Literature DB >> 31773001

Unresectable Ameloblastoma Successfully Treated with Definitive Proton Therapy.

Francesco Dionisi1, Maurizio Amichetti1, Carlo Algranati2, Irene Giacomelli1, Mattia Barbareschi3, Mauro Recla4, Cesare Grandi5.   

Abstract

We report the case of an 87-year-old man affected by an unresectable ameloblastoma of the right jaw that was successfully treated by definitive proton therapy up to a dose of 66 Gy in 33 fractions. Treatment was well tolerated, and there were no interruptions due to toxicity. At follow-up visits, the patient experienced complete response to treatment with no evidence of disease and complete recovery from acute side effects. In this report, we discuss the potential and possible pitfalls of proton therapy in the treatment of specific settings. © Copyright 2017 International Journal of Particle Therapy.

Entities:  

Keywords:  ameloblastoma; head and neck cancer; paranasal sinus cancer; proton therapy

Year:  2017        PMID: 31773001      PMCID: PMC6871656          DOI: 10.14338/IJPT-17-00008.1

Source DB:  PubMed          Journal:  Int J Part Ther        ISSN: 2331-5180


  18 in total

1.  Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach.

Authors:  Johannes A Langendijk; Philippe Lambin; Dirk De Ruysscher; Joachim Widder; Mike Bos; Marcel Verheij
Journal:  Radiother Oncol       Date:  2013-06-05       Impact factor: 6.280

Review 2.  New challenges in high-energy particle radiobiology.

Authors:  M Durante
Journal:  Br J Radiol       Date:  2014-03       Impact factor: 3.039

3.  Establishing Evidence-Based Indications for Proton Therapy: An Overview of Current Clinical Trials.

Authors:  Mark V Mishra; Sameer Aggarwal; Soren M Bentzen; Nancy Knight; Minesh P Mehta; William F Regine
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-11-08       Impact factor: 7.038

4.  First Clinical Investigation of Cone Beam Computed Tomography and Deformable Registration for Adaptive Proton Therapy for Lung Cancer.

Authors:  Catarina Veiga; Guillaume Janssens; Ching-Ling Teng; Thomas Baudier; Lucian Hotoiu; Jamie R McClelland; Gary Royle; Liyong Lin; Lingshu Yin; James Metz; Timothy D Solberg; Zelig Tochner; Charles B Simone; James McDonough; Boon-Keng Kevin Teo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-02-04       Impact factor: 7.038

5.  Feasibility and toxicity of concurrent chemoradiation for elderly patients with head and neck cancer.

Authors:  Megan E Daly; Derick H Lau; D Gregory Farwell; Quang Luu; Paul J Donald; Allen M Chen
Journal:  Am J Otolaryngol       Date:  2013-08-15       Impact factor: 1.808

Review 6.  Ameloblastoma.

Authors:  William M Mendenhall; John W Werning; Rui Fernandes; Robert S Malyapa; Nancy P Mendenhall
Journal:  Am J Clin Oncol       Date:  2007-12       Impact factor: 2.339

7.  Treatment of ameloblastoma and ameloblastic carcinoma with radiotherapy.

Authors:  William R Kennedy; John W Werning; Frederic J Kaye; William M Mendenhall
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-01-21       Impact factor: 2.503

8.  Effectiveness of robust optimization in intensity-modulated proton therapy planning for head and neck cancers.

Authors:  Wei Liu; Steven J Frank; Xiaoqiang Li; Yupeng Li; Peter C Park; Lei Dong; X Ronald Zhu; Radhe Mohan
Journal:  Med Phys       Date:  2013-05       Impact factor: 4.071

9.  Prominent response with helical tomotherapy in recurrent ameloblastic carcinoma of maxillary sinus: a case report.

Authors:  Timur Koca; Hamit Başaran; Deniz Arslan; Duygu Sezen; Zümrüt Arda Cerkeşli; Ozlem Kılınç; Sibel Karaca; Cumhur Ibrahim Başsorgun; Hilmi Onder Okay; Münir Demirci
Journal:  Radiat Oncol       Date:  2014-07-15       Impact factor: 3.481

10.  Acute toxicity in comprehensive head and neck radiation for nasopharynx and paranasal sinus cancers: cohort comparison of 3D conformal proton therapy and intensity modulated radiation therapy.

Authors:  Mark W McDonald; Yuan Liu; Michael G Moore; Peter A S Johnstone
Journal:  Radiat Oncol       Date:  2016-02-27       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.